Men's Health News

RSS

Bayer to present Phase I and II clinical trial data of Alpharadin in CRPC at 46th ASCO

Bayer HealthCare will present a combined analysis from Phase I and II clinical trials evaluating the safety and efficacy of one of its lead investigational cancer treatments, Alpharadin™ (radium-223 chloride), in castration-resistant prostate cancer (CRPC) that has spread to the bones (metastases).

4 Jun 2010

Ongoing clinical development program for NX-1207 for treatment of BPH highlighted

Nymox Pharmaceutical Corporation is pleased to report on the presentation of new positive data at a high-level symposium and panel discussion held at the Annual Meeting of the American Urological Association in San Francisco. The symposium was held between 6:00 and 7:00 pm EDT on Tuesday. The well-attended symposium highlighted the ongoing clinical development program for NX-1207 for the treatment of benign prostatic hyperplasia and featured expert panel discussions on the new therapy.

4 Jun 2010

Testosterone deficiency can lead to multiple disorders

Almost a quarter of men treated for cancer in their childhood suffer from a deficiency of the male sex hormone testosterone.

3 Jun 2010

Light therapy may be alternative treatment for prostate cancer

Cliff Berkman is working on a better way—one that specifically targets prostate cancer cells and causes a type of natural death that spares surrounding tissues from damage.

3 Jun 2010

Shionogi Pharma presents study results of PSD502 for treatment of primary PE at AUA 2010

Shionogi Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd., today presented data summarizing the results of two pivotal studies of the investigational new drug PSD502, a topical metered dose spray being developed for the treatment of primary premature ejaculation. These data were presented at the 2010 American Urological Association Annual Meeting in San Francisco.

2 Jun 2010

TQ can suppress growth of aggressive PCa cell lines: Researchers

Researchers at the Tulane University School of Medicine, in New Orleans, LA, have demonstrated that thymoquinone a major component of black seed oil (Nigella sativa) can suppress the growth of several aggressive prostate cancer cell lines, in vitro. Although previous studies have shown the anti-proliferative effects of TQ in different types of cancers, the molecular mechanism of this effect of TQ had not been delineated.

2 Jun 2010

Men who refuse surgery for prostate cancer have 51% overall survival rate: Study

Men who refuse surgery for prostate cancer and instead opt for "watchful waiting" - monitoring cancer progression without undergoing treatment - have a significantly worse long-term survival rate than those patients that choose radiotherapy, according to researchers at Henry Ford Hospital in Detroit.

2 Jun 2010

Phase 3 pivotal REVIVE study data of VIVUS' avanafil for ED presented at 2010 AUA

VIVUS, Inc. today announced that data from the previously reported phase 3 pivotal REVIVE (TA-301) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED), were presented at the American Urological Association (AUA) 2010 Annual Meeting.

2 Jun 2010

Men with ED are at increased risk of high CACS: Researchers

In the largest study to date evaluating erectile dysfunction and coronary artery calcification, researchers at Mount Sinai School of Medicine have determined that men with ED are at a significantly increased risk of high coronary artery calcification scores, a known predictor of future cardiovascular events.

2 Jun 2010

Study results show calcium consumption increases prostate cancer risk in Chinese

Among Chinese men, calcium consumption — even at relatively low levels and from non-dairy food sources such as soy, grains and green vegetables — may increase prostate cancer risk, according to results published in Cancer Research, a journal of the American Association for Cancer Research.

2 Jun 2010

Shionogi Pharma presents data on PSD502 pivotal studies for primary premature ejaculation at 2010 AUA

Shionogi Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd., today presented data summarizing the results of two pivotal studies of the investigational new drug PSD502, a topical metered dose spray being developed for the treatment of primary premature ejaculation (PE). These data were presented at the 2010 American Urological Association (AUA) Annual Meeting in San Francisco.

1 Jun 2010

Dendreon announces data presentation from 4 PROVENGE clinical trials at 105th AUA annual meeting

Dendreon Corporation today announced the presentation of safety data from the integrated analysis of four randomized PROVENGE® (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in prostate cancer at the 105th Annual Scientific Meeting of the American Urological Association (AUA) in San Francisco.

1 Jun 2010

Surgery more beneficial than drug therapy for benign prostatic hyperplasia

A 17-year-long community study looking at symptoms of enlarged prostate in over 2,000 men age 40 to 79 years suggests that surgery for benign prostatic hyperplasia (BPH) offers more relief from incontinence and obstruction symptoms than treatment from drug-based therapy, according to a new study by researchers at Mayo Clinic.

31 May 2010

Rates of men dying from skin cancer double in last 30 years

The rates of men dying from malignant melanoma - the deadliest form of skin cancer - have doubled in the last 30 years, according to the latest Cancer Research UK figures published today.

31 May 2010

AMS issued U.S. patent covering surgical methodology for implanting AdVance Male Sling

American Medical Systems, a leading provider of world-class devices and therapies for both male and female pelvic health, announced today that the United States Patent and Trademark Office has issued U.S. Patent Number 7,686,760 covering the surgical methodology for implanting the AMS AdVance® Male Sling. This patent provides AMS with broad patent coverage on transobturator surgical procedures to treat male incontinence.

29 May 2010

Researchers discover method to select sperm with highest DNA integrity

Researchers at Yale School of Medicine have discovered a method to select sperm with the highest DNA integrity in a bid to improve male fertility. The method is comparable to that of the egg's natural selection abilities, according to the study published in the June/July issue of the Journal of Andrology.

29 May 2010

New GreenLight XPS Laser System launched for treatment of BPH

American Medical Systems, a leading provider of world-class devices and therapies for both male and female pelvic health, today announced the launch and immediate availability of its new GreenLight XPS (Xcelerated Performance System) for laser treatment of benign prostatic hyperplasia or enlarged prostate.

29 May 2010

VIVUS to present phase 3 data on avanafil for treatment of ED at AUA 2010

VIVUS, Inc. today announced that phase 3 data on avanafil, a next generation oral phosphodiesterase type 5 inhibitor therapy being investigated for the treatment of erectile dysfunction, will be presented next Tuesday at the American Urological Association 2010 Annual Meeting in San Francisco, California.

28 May 2010

Northwestern Memorial performs robotic assisted vasectomy reversal using da Vinci surgical robot

In 1989 a 29-year-old Michael Schrader had it all: steady job, a wife, and two wonderful children-daughter Courtney and son Cameron. He couldn't envision wanting more-that is, more children. Taking steps to keep his nuclear family intact, he underwent vasectomy- a procedure so routine he was back on the golf course the next afternoon.

28 May 2010

Amgen announces European approval of Prolia

Amgen Inc. today announced that the European Commission (EC) has granted marketing authorization for Prolia® (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.

28 May 2010

Men's Health News

Bayer to present Phase I and II clinical trial data of Alpharadin in CRPC at 46th ASCO

Ongoing clinical development program for NX-1207 for treatment of BPH highlighted

Testosterone deficiency can lead to multiple disorders

Light therapy may be alternative treatment for prostate cancer

Shionogi Pharma presents study results of PSD502 for treatment of primary PE at AUA 2010

TQ can suppress growth of aggressive PCa cell lines: Researchers

Men who refuse surgery for prostate cancer have 51% overall survival rate: Study

Phase 3 pivotal REVIVE study data of VIVUS' avanafil for ED presented at 2010 AUA

Men with ED are at increased risk of high CACS: Researchers

Study results show calcium consumption increases prostate cancer risk in Chinese

Shionogi Pharma presents data on PSD502 pivotal studies for primary premature ejaculation at 2010 AUA

Dendreon announces data presentation from 4 PROVENGE clinical trials at 105th AUA annual meeting

Surgery more beneficial than drug therapy for benign prostatic hyperplasia

Rates of men dying from skin cancer double in last 30 years

AMS issued U.S. patent covering surgical methodology for implanting AdVance Male Sling

Researchers discover method to select sperm with highest DNA integrity

New GreenLight XPS Laser System launched for treatment of BPH

VIVUS to present phase 3 data on avanafil for treatment of ED at AUA 2010

Northwestern Memorial performs robotic assisted vasectomy reversal using da Vinci surgical robot

Amgen announces European approval of Prolia

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest News